Company Description
BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers.
Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.
The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9).
In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.
| Country | United States |
| Founded | 2015 |
| IPO Date | Jun 27, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 556 |
| CEO | Neil Kumar |
Contact Details
Address: 3160 Porter Drive, Suite 250 Palo Alto, California 94304 United States | |
| Phone | 650 391 9740 |
| Website | bridgebio.com |
Stock Details
| Ticker Symbol | BBIO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001743881 |
| CUSIP Number | 10806X102 |
| ISIN Number | US10806X1028 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Eric Michael David J.D., M.D., Ph.D. | Chief Executive Officer of Gene Therapy |
| Dr. Neil Kumar Ph.D. | Co-Founder, Chief Executive Officer and Director |
| Dr. Charles J. Homcy M.D. | Co-Founder, Chairman of Pharmaceuticals and Independent Lead Director |
| Dr. Frank P. McCormick Ph.D. | Co-Founder, Chairman of Oncology and Director |
| Dr. Brian C. Stephenson C.F.A., Ph.D. | Chief Financial Officer and Secretary |
| Dr. Richard H. Scheller Ph.D. | Chairman of Research and Development |
| Dr. Thomas Trimarchi Ph.D. | President and Chief Operating Officer |
| Dr. Uma Sinha Ph.D. | Chief Scientific Officer |
| Grace Rauh | Vice President of Communications |
| Eli M. Wallace Ph.D. | Chief Scientific Officer of Oncology |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |
| Nov 6, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Oct 22, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Sep 17, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Sep 13, 2024 | 144 | Filing |
| Sep 11, 2024 | 8-K | Current Report |
| Aug 21, 2024 | 8-K | Current Report |
| Aug 20, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |